company background image
GLAXO logo

GlaxoSmithKline Pakistan KASE:GLAXO Stock Report

Last Price

PK₨140.02

Market Cap

PK₨44.6b

7D

-0.2%

1Y

93.9%

Updated

21 Jun, 2024

Data

Company Financials

GlaxoSmithKline Pakistan Limited

KASE:GLAXO Stock Report

Market Cap: PK₨44.6b

GLAXO Stock Overview

Operates as a biopharma company in Pakistan and internationally.

GLAXO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health6/6
Dividends0/6

GlaxoSmithKline Pakistan Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GlaxoSmithKline Pakistan
Historical stock prices
Current Share PricePK₨140.02
52 Week HighPK₨145.99
52 Week LowPK₨68.00
Beta0.33
11 Month Change3.46%
3 Month Change66.39%
1 Year Change93.91%
33 Year Change-16.42%
5 Year Change46.88%
Change since IPO365.47%

Recent News & Updates

Recent updates

Shareholder Returns

GLAXOPK PharmaceuticalsPK Market
7D-0.2%-0.7%2.0%
1Y93.9%87.9%65.5%

Return vs Industry: GLAXO exceeded the PK Pharmaceuticals industry which returned 91.3% over the past year.

Return vs Market: GLAXO exceeded the PK Market which returned 64.4% over the past year.

Price Volatility

Is GLAXO's price volatile compared to industry and market?
GLAXO volatility
GLAXO Average Weekly Movement6.7%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement5.3%
10% most volatile stocks in PK Market8.2%
10% least volatile stocks in PK Market3.2%

Stable Share Price: GLAXO's share price has been volatile over the past 3 months.

Volatility Over Time: GLAXO's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of PK stocks.

About the Company

FoundedEmployeesCEOWebsite
20011,700Erum Rahimwww.pk.gsk.com

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan and internationally. It deals in anti-infective, dermatology, respiratory, analgesics, immunology, oncology, urology, HIV, vaccines, and analgesics therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Cutivate, Calpol, Boostrix, Rotarix, Havrix, and Synflorix.

GlaxoSmithKline Pakistan Limited Fundamentals Summary

How do GlaxoSmithKline Pakistan's earnings and revenue compare to its market cap?
GLAXO fundamental statistics
Market capPK₨44.59b
Earnings (TTM)PK₨668.67m
Revenue (TTM)PK₨53.88b

66.7x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GLAXO income statement (TTM)
RevenuePK₨53.88b
Cost of RevenuePK₨49.31b
Gross ProfitPK₨4.57b
Other ExpensesPK₨3.90b
EarningsPK₨668.67m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.10
Gross Margin8.49%
Net Profit Margin1.24%
Debt/Equity Ratio0%

How did GLAXO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.